Comparison · NCT02614794-deaths
Tuc+Cap+Tra vs Pbo+Cap+Tra: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tuc+Cap+Tra vs Pbo+Cap+Tra: deaths from any cause. Trial comparisons, record NCT02614794-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02614794-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.639 | 0.591 | 0.684 | wilson | |
| Risk in group 2 | 0.752 | 0.689 | 0.807 | wilson | |
| Risk difference, group 1 minus group 2 | -0.113 | -0.186 | -0.0353 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.849 | 0.763 | 0.946 | log | |
| Odds ratio, group 1 over group 2 | 0.582 | 0.399 | 0.85 | log | |
| Number needed to treat, for one fewer death from any cause on Tuc+Cap+Tra than on Pbo+Cap+Tra | 8.81 | 5.38 | 28.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tuc+Cap+Tra | Tucatinib in combination with capecitabine \& trastuzumab | 262 | 410 | EG000 |
| Group 2 | Pbo+Cap+Tra | Placebo in combination with capecitabine \& trastuzumab | 152 | 202 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Non-serious Adverse Events, Serious Adverse Events, and All-Cause Mortality were followed for up to 60.1 months
Source ClinicalTrials.gov
Trial
- Title
- A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
- NCT number
- NCT02614794
- Phases
- PHASE2
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- tucatinib, capecitabine, trastuzumab, placebo
- Lead sponsor
- Seagen Inc.
- Results first posted
- 2020-09-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02614794?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02614794-deaths